C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

Zelalem Temesgen; Colleen F Kelley; Frank Cerasoli; Adrian Kilcoyne; Dale Chappell; Cameron Durrant; Omar Ahmed; Gabrielle Chappell; Victoria Catterson; Christopher Polk; Andrew Badley; Vincent C Marconi

doi:10.1136/thoraxjnl-2022-218744

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Hosted content

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Respiratory infection

Original research

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Temesgen Z, Kelley CF, Cerasoli F LIVE-AIR Study Group, et al

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

Thorax 2023;78:606-616.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password